Targeting Survivin to Impact Cancer Cell Fate
Author Information
Author(s): Kelly Ronan J, Lopez-Chavez Ariel, Citrin Deborah, Janik John E, Morris John C
Primary Institution: National Cancer Institute
Hypothesis
Can targeting the inhibitor of apoptosis protein survivin improve cancer treatment outcomes?
Conclusion
Targeting survivin may enhance the effectiveness of cancer therapies by overcoming resistance and improving patient outcomes.
Supporting Evidence
- Survivin is highly expressed in many cancers and is linked to poor clinical outcomes.
- Inhibiting survivin can sensitize cancer cells to chemotherapy and radiation.
- Clinical trials show that survivin inhibitors may improve treatment responses in various cancers.
Takeaway
Survivin is a protein that helps cancer cells survive, and by blocking it, we can make cancer treatments work better.
Methodology
The review discusses various studies and clinical trials involving survivin inhibitors and their effects on cancer treatment.
Potential Biases
Potential biases in study designs and treatment variations across trials may affect the interpretation of survivin's role in cancer.
Limitations
The review highlights challenges in correlating survivin expression with clinical outcomes due to small sample sizes and varying treatment regimens.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website